{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(2)"],"submitter":["Lim SH"],"pubmed_abstract":["We investigated the patients with solid cancers harboring Fms-like tyrosine kinase 3 (FLT3) amplification using targeted sequencing of tumor tissue specimen and FISH assay. Simultaneously, FLT3-amplified patient-derived cells (PDCs) were generated to evaluate the sensitivity to FLT3 inhibition. A patient with metastatic colon cancer who was previously treated with more than 3rd line cytotoxic chemotherapy was found to have FLT3 amplification and then received regorafenib showing partial response. In two PDC cell lines with FLT3 amplification, FLT3 mRNA expression was increased, however, the growth of tumor cells was not significantly inhibited by either regorafenib or sorafenib which is known to block the activity FLT3. Additional drug combinations with mTOR inhibitor did not affect the ce"],"journal":["Oncotarget"],"pagination":["3237-3245"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5356878"],"repository":["biostudies-literature"],"pubmed_title":["The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors."],"pmcid":["PMC5356878"],"pubmed_authors":["Park YS","Kim SY","Lee SJ","Park K","Kim KM","Kim ST","Lee SH","Kim K","Lee J","Jang H","Park JO","Lim HY","Lim SH","Park W","Kang WK","Kim NK","Park SH","Ahn S"],"additional_accession":[]},"is_claimable":false,"name":"The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors.","description":"We investigated the patients with solid cancers harboring Fms-like tyrosine kinase 3 (FLT3) amplification using targeted sequencing of tumor tissue specimen and FISH assay. Simultaneously, FLT3-amplified patient-derived cells (PDCs) were generated to evaluate the sensitivity to FLT3 inhibition. A patient with metastatic colon cancer who was previously treated with more than 3rd line cytotoxic chemotherapy was found to have FLT3 amplification and then received regorafenib showing partial response. In two PDC cell lines with FLT3 amplification, FLT3 mRNA expression was increased, however, the growth of tumor cells was not significantly inhibited by either regorafenib or sorafenib which is known to block the activity FLT3. Additional drug combinations with mTOR inhibitor did not affect the ce","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Jan","modification":"2025-04-04T14:33:29.454Z","creation":"2019-03-26T23:46:30Z"},"accession":"S-EPMC5356878","cross_references":{"pubmed":["27906677"],"doi":["10.18632/oncotarget.13700"]}}